申请人:NATCO PHARMA LIMITED
公开号:US20170114057A1
公开(公告)日:2017-04-27
The present invention relates to novel antiproliferative 1H-1,8-naphthyridin-2-ones of the general formula (I) or pharmaceutically acceptable salts thereof: In which the variable groups are as defined herein, and their preparation and use in therapeutic treatment of disorders related to inhibition of tyrosine kinases in warm blooded animals. The compounds can overcome imatinib induced drug resistance.